Prevention of Recurrent PPROM in Subsequent Pregnancy

Recommended Intervention

The American College of Obstetricians and Gynecologists recommends 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly starting at 16-20 weeks until 36 weeks for women with a history of spontaneous preterm birth, including PPROM, as the standard of care based on SMFM and ACOG recommendations 1, 2
Progesterone supplementation starting at 16-20 weeks is the most appropriate intervention for preventing recurrent preterm birth in a woman with a history of previous PPROM, though evidence specifically for PPROM prevention is limited 1, 2

In subsequent pregnancies after previable or periviable PPROM, guidelines recommend following the same management as for any pregnant person with a previous spontaneous preterm birth, including progesterone supplementation starting in the second trimester 1, 2, 3
The risk of recurrent preterm birth after PPROM at <24 weeks is substantial: nearly 50% of subsequent pregnancies result in recurrent preterm birth, with 30% at <34 weeks and 17% at <24 weeks 3
17P has demonstrated efficacy in reducing preterm birth in women with prior spontaneous preterm birth, with reductions in delivery at <37, <35, and <32 weeks of gestation 1, 2

There is insufficient evidence to recommend progestogens specifically for preventing PPROM itself 1
Progestogens have not been proven to prevent PPROM as a complication, but they do reduce the overall risk of recurrent preterm birth in women with prior spontaneous preterm birth 1

Bed rest has no proven benefit for preventing preterm birth or PPROM and is not recommended, lacking evidence-based support and may cause harm through deconditioning and thromboembolic risk 1
While cervical length monitoring can identify women who might benefit from additional interventions, it is not a preventive intervention itself 1, 2

The optimal approach includes starting 17P 250 mg intramuscularly weekly at 16-20 weeks of gestation and continuing until 36 weeks of gestation or delivery 1, 2
Consider adding transvaginal ultrasound cervical length screening, as women with both prior preterm birth and short cervix (<25 mm) may benefit from cerclage 1

Only 45% of women with prior previable PPROM in one study received progesterone or cerclage, and outcomes were similar regardless, suggesting the benefit may be modest in this specific population 3
The only factor independently associated with recurrent preterm birth after previable PPROM was a history of another previous preterm birth (beyond the PPROM pregnancy itself) 3
Vaginal progesterone has not been adequately proven to reduce recurrent preterm birth in women with prior spontaneous preterm birth in multiple high-quality RCTs, despite heterogeneity in dosing and populations 2